Guidance: Determining Whether to Submit an ANDA or a 505(b)(2) Application
FDA issued guidance clarifying when to submit an ANDA versus a 505(b)(2) application, affecting drug approval pathways.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on August 17, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, and compounding outsourcing facilities (503B). should confirm how it applies to their specific situation before acting. There is a time constraint attached: No specific deadline; guidance is effective immediately.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
New FDA guidance provides criteria for determining whether a product should be submitted as an ANDA or a 505(b)(2) application.
Who it affects
Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, and compounding outsourcing facilities (503B).
What you must do
Review the guidance to ensure your current and pipeline products are filed under the correct application type.
Deadline
No specific deadline; guidance is effective immediately.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- FDA drafts guidance on using next-generation sequencing to assess gene therapy safety - raps.org
- FDA proposes rule to ease registration for distributed manufacturers, require foreign API sites to register - raps.org
- FDA proposes rule to streamline drug manufacturing registration By Investing.com - Investing.com Canada
- Not Joking Around: FDA Offers Additional Clarification on Compounded GLP-1 Policy in April Fool’s Day Announcement - natlawreview.com
- Congress Introduces SAFE Drugs Act of 2025, Expanding FDA Oversight of Compounded GLP-1 Drugs and Telehealth Providers - dykema.com